

**161<sup>st</sup> SEIAA, A.P.**

**2nd Day**



**AGENDA NOTES FOR THE 161<sup>st</sup> MEETING OF STATE LEVEL  
ENVIRONMENT IMPACT ASSESSMENT AUTHORITY (SEIAA)  
A.P., TO BE HELD 31.08.2021 AT VIJAYAWADA, AP.  
( video conference)**

**Present:**

**The following members were present:**

1.	Sri P.Venkata Rami Reddy, I.A.S, (Retired).	Chairman
2.	Dr. Thatiparthi Byragi Reddy Professor. Department of Environmental Sciences, Andhra University, Visakhapatnam	Member
3.	Dr. P.V.Chalapathi Rao, I.F.S Special Secretary to Govt., Environment, Forests, Sciences and Technology Department, Govt. of Andhra Pradesh & Member Secretary, SEIAA,A.P.	Member Secretary

01/09/2021

<b>Agenda Item:</b> <b>164.22 &amp; 161.21</b>	<b>Proposal of establishment of Bulk drugs and intermediates manufacturing unit by M/s. Aanviksha Laboratories Private Limited at Plot No.51, YSR Jagananna Mega Industrial Hub in Kopparthi Industrial Estate, Kadapa, Y.S.R. District, Andhra Pradesh</b> <span style="float: right;">SIA/AP/IND2/206334/2021</span>
	<p>Recommendations of the SEAC on 27.07.2021:</p> <p><b>Category : B2-5(f)-API</b></p> <p>The Proposal of <b>M/s. Aanviksha Laboratories Private Limited.</b>, is for Environmental Clearance for production quantities <b>of the bulk drug &amp; Intermediates – 58 MT/Month.</b> The project proponent and their Consultant, M/s. Pridhvi Envirotech Pvt.Ltd have attended the meeting. MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised, as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006-Synthetic organic chemicals industry (dyes &amp; dye intermediates &amp; bulk drug and intermediates). The Committee noted that this is a bulk drug &amp; intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug &amp; Intermediates manufacturing unit with production capacity: <b>58 MT/Month.</b> The project proponent has submitted the EMP, PFR, Risk Assessment Reports. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for <b>issue of Environmental Clearance</b> for manufacture of <b>Bulk Drug and Intermediates with production quantity – 58 MT/Month</b> duly stipulating a condition that the project proponent shall submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC and to <b>issue Environmental Clearance with a</b> condition that the project proponent shall allocate funds of 2% of the project cost as a part of CER activity as per the OM F No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&amp;CC and other instructions issued from time-to-time and this shall be monitored by PCB.</p>
<b>Agenda Item:</b> <b>164.23 &amp; 161.22</b>	<b>Expansion proposal for manufacturing of Bulk Drugs in the existing unit located Plot. No. 45, IDA, Pydibheemavaram Village, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh by M/s Synpure Labs India Pvt. Ltd</b>
	<p>Recommendations of the SEAC on 27.07.2021:</p> <p><b>Category : B2-5(f)-API</b></p> <p>The Proposal of <b>M/s Synpure Labs India Pvt. Ltd.</b>, is for Environmental Clearance for production quantities <b>of the bulk drug &amp; Intermediates – 19.4 TPM.</b> The project proponent and their Consultant, M/s. Pridhvi Envirotech (P)</p>

	<p>Ltd. have attended the meeting. MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes &amp; dye intermediates &amp; bulk drug and intermediates). The Committee noted that this is a bulk drug &amp; intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug &amp; Intermediates manufacturing unit with production capacity: <b>19.4 TPM</b>. The project proponent has submitted the EMP, PFR, Risk Assessment Reports. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for <b>issue of Environmental Clearance</b> for manufacture of <b>Bulk Drug and Intermediates with production quantity – 19.4 TPM</b> duly stipulating a condition that the project proponent shall submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC and to <b>issue Environmental Clearance with a</b> condition that the project proponent shall allocate funds of 2% of the project cost as a part of CER activity as per the OM F No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&amp;CC and other instructions issued from time-to-time and this shall be monitored by PCB.</p>
<p><b>Agenda Item:</b> <b>164.24 &amp; 161.23</b></p>	<p><b>Proposal of establishment of Bulk drugs and intermediates manufacturing unit by M/s. Lakshana Biotechnologies Private Limited at Sy. No. 206/2, 208/2, Tellapadu Village, Tarlupadu Grama Panchayat, Tarlupadu Mandal, Markapuram, Prakasham District Andhra Pradesh</b> SIA/AP/IND2/206730/2021</p>
	<p>Recommendations of the SEAC on 27.07.2021: <b>Category : B2-5(f)-API</b> The Proposal of <b>M/s. Lakshana Biotechnologies Private Limited.,</b> is for Environmental Clearance for production quantities <b>of the bulk drug &amp; Intermediates – 18 Tons/Month.</b> The project proponent and their Consultant M/s. AM Enviro Engineers have attended the meeting. MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to</p>

	<p>31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006-Synthetic organic chemicals industry (dyes &amp; dye intermediates &amp; bulk drug and intermediates). The Committee noted that this is a bulk drug &amp; intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug &amp; Intermediates manufacturing unit with production capacity: <b>18 Tons/Month</b>. The project proponent has submitted the EMP, PFR, Risk Assessment Reports. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for <b>issue of Environmental Clearance</b> for manufacture of <b>Bulk Drug and Intermediates with production quantity – 18 Tons/Month</b> duly stipulating a condition that the project proponent shall submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC and to <b>issue Environmental Clearance with a</b> condition that the project proponent shall allocate funds of 2% of the project cost as a part of CER activity as per the OM F No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&amp;CC and other instructions issued from time-to-time and this shall be monitored by PCB.</p>
<p><b>Agenda Item: 164.26 &amp; 161.24</b></p>	<p><b>Proposal of establishment of Active Pharmaceutical Ingredients manufacturing industry at Sy. No. 1048 B, 1428 B, 1428 C &amp; 1438 Adigoppala Village, Durgi Mandal, Guntur District Andhra Pradesh by M/s. Shree Jaya Laboratories Pvt. Ltd– SIA/AP/IND2/206751/2021</b></p>
	<p>Recommendations of the SEAC on 27.07.2021:</p> <p><b>Category : B2-5(f)-API</b></p> <p>The Proposal of <b>M/s. Shree Jaya Laboratories Pvt. Ltd.,</b> is for Environmental Clearance for production quantities <b>of the bulk drug &amp; Intermediates – 285 MT/month</b>. The project proponent and their Consultant M/s. SV Enviro Labs and Consultants have attended the meeting. MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised, as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes &amp; dye intermediates &amp; bulk drug and intermediates). The Committee noted that this is a bulk drug &amp; intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug &amp; Intermediates manufacturing unit with production capacity: <b>285 MT/month</b>. The project proponent has submitted the EMP, PFR, Risk Assessment Reports. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The</p>

	<p>Committee after examining the project proposals, presentations and deliberations recommended for <b>issue of Environmental Clearance</b> for manufacture of <b>Bulk Drug and Intermediates with production quantity – 285 MT/month</b> duly stipulating a condition that the project proponent shall submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC and to <b>issue Environmental Clearance with a</b> condition that the project proponent shall allocate funds of 2% of the project cost as a part of CER activity as per the OM F No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&amp;CC and other instructions issued from time-to-time and this shall be monitored by PCB.</p>
<p><b>Agenda Item:</b> <b>164.27 &amp; 161.25</b></p>	<p><b>Active Pharma Ingredients (Bulk drugs and intermediates) manufacturing unit by M/s. K.C.P. Sugar &amp; Industries Corporation Limited at Sy. Nos. 952 (Part), 954 (Part), 955 (Part), 956 (Part), 957 (Part), Lakshmipuram Village, Challapalli Mandal, Krishna District, Andhra Pradesh</b> SIA/AP/IND2/206836/2021</p>
	<p>Recommendations of the SEAC on 27.07.2021:</p> <p><b>Category : B2-5(f)-API</b></p> <p>The Proposal of <b>M/s. K.C.P. Sugar &amp; Industries Corporation Limited.,</b> is for Environmental Clearance for production quantities <b>of the bulk drug &amp; Intermediates – 420 TPM.</b> The project proponent and their Consultant, M/s. Team Labs and Consultants have attended the meeting. MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006-Synthetic organic chemicals industry (dyes &amp; dye intermediates &amp; bulk drug and intermediates). The Committee noted that this is a bulk drug &amp; intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug &amp; Intermediates manufacturing unit with production capacity: <b>420 TPM.</b> The project proponent has submitted the EMP, PFR, Risk Assessment Reports.</p> <p>The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for <b>issue of Environmental Clearance</b> for manufacture of <b>Bulk Drug and Intermediates with production quantity – 420 TPM</b> duly stipulating a condition that the project proponent shall submit (i). Permission from Ground Water Department for withdrawal of required quantity of groundwater (ii) An undertaking that they allocate funds of 2% of the project cost as a part of CER</p>

	<p>activity.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC and to <b>issue Environmental Clearance with a</b> condition that the project proponent shall allocate funds of 2% of the project cost as a part of CER activity as per the OM F No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&amp;CC and other instructions issued from time-to-time and this shall be monitored by PCB.</p>
<b>Agenda Item: 164.28 &amp; 161.26</b>	<p><b>“High Rise Hospital Building” of M/s. Lalitha PVS Institute of Medical Sciences Private Limited, Dy. No; 572, 572-A1, 573, 573-A-1, 573-A-2-1, 573/D, 574/3A &amp; 3B, 575/3, 575-3B1, at NH -16 Highway Road, Lalitha Nagar, Guntur Municipal Corporation, Guntur, Andhra Pradesh State.</b> SIA/AP/MIS/207122/2021</p>
	<p>Recommendations of the SEAC on 27.07.2021:</p> <p><b>Category : B2</b></p> <p>The proponent and their consultant, M/s SV Enviro labs &amp; consultants have attended the meeting. The Committee noted that the project proponent proposes for construction of Residential building project with <b>Built Up area - 1,02,992.64</b> Sqm. Further the Committee noted that the proposed project falls under Item 8(a) of the schedule of the EIA Notification 2006- Construction projects , as the proposed project site covering an area is &lt; 50 ha and built up area is &lt;1,50,000 sq. m. The present proposal comes under category ‘B2’ project. The Committee after examining the project proposals, presentations, MoEF&amp;CC’ Notifications &amp; OMs and detailed deliberations, recommended <b>for issue of Environmental Clearance</b> duly stipulating a condition that (i) The project proponent shall construct the STP for the treatment and disposal of domestic effluents (ii) The project proponent shall submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC and to <b>issue Environmental Clearance with a</b> condition that the project proponent shall i) construct the STP for the treatment and disposal of domestic effluents ii) allocate funds of 2% of the project cost as a part of CER activity as per the OM F No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&amp;CC and other instructions issued from time-to-time and this shall be monitored by PCB.</p>
<b>Agenda Item: 164.30 &amp; 161.27</b>	<p><b>Proposed API Manufacturing Facility of M/s. Lukra Pharmaceuticals Private Limited at survey No. 26,27,173/12, Naruva Village, Ranastalam Taluk, Srikakulam District, Andhra Pradesh.</b> SIA/AP/IND2/206913/2021</p>
	<p>Recommendations of the SEAC on 27.07.2021:</p> <p><b>Category : B2-5(f)-API</b></p> <p>The Proposal of <b>M/s. Lukra Pharmaceuticals Private Limited.,</b> is for Environmental Clearance for production quantities <b>of the bulk drug &amp; Intermediates – 6240 TPA.</b> The project proponent and their Consultant, M/s. Hubert Enviro Care Systems (P) LTD have attended the meeting. MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API),</i></p>



	<p>received up to the 30th September 2020, shall be appraised, as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time." and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes &amp; dye intermediates &amp; bulk drug and intermediates). The Committee noted that this is a bulk drug &amp; intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug &amp; Intermediates manufacturing unit with production capacity: <b>6240 TPA</b>. The project proponent has submitted the EMP, PFR, Risk Assessment Reports. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for <b>issue of Environmental Clearance</b> for manufacture of <b>Bulk Drug and Intermediates with production quantity – 6240 TPA</b> duly stipulating a condition that the project proponent shall submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC and to <b>issue Environmental Clearance with a</b> condition that the project proponent shall allocate funds of 2% of the project cost as a part of CER activity as per the OM F No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&amp;CC and other instructions issued from time-to-time and this shall be monitored by PCB.</p>
<p><b>Agenda Item: 164.31 &amp; 161.28</b></p>	<p>Proposed Establishment of Active Pharmaceutical Ingredients (APIs) and API Intermediates Manufacturing unit along with R&amp;D Products, 4.2 MW CPP &amp; 5 MW Solar Power Plant by M/s. Cyclic Life Sciences Private Limited at Sy. Nos. 952 (Part), 954 (Part), 955 (Part), 956 (Part), 957 (Part), Lakshmipuram Village, Challapalli Mandal, Krishna District, Andhra Pradesh. SIA/AP/IND2/207034/2021</p>
	<p>Recommendations of the SEAC on 27.07.2021:</p> <p><b>Category : B2-5(f)-API</b></p> <p>The Proposal of <b>M/s. Cyclic Life Sciences Private Limited.</b>, is for Environmental Clearance for production quantities <b>of the bulk drug &amp; Intermediates – 5000.16 TPA</b>. The project proponent and their Consultant, M/s.. KKB Envirocare Consultants Pvt. Ltd have attended the meeting. MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes &amp; dye intermediates</p>



	<p>&amp; bulk drug and intermediates). The Committee noted that this is a bulk drug &amp; intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug &amp; Intermediates manufacturing unit with production capacity: <b>5000.16 TPA</b>. The project proponent has submitted the EMP, PFR, Risk Assessment Reports. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for <b>issue of Environmental Clearance</b> for manufacture of <b>Bulk Drug and Intermediates with production quantity – 5000.16 TPA</b> duly stipulating a condition that the project proponent shall submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC and to <b>issue Environmental Clearance with a</b> condition that the project proponent shall allocate funds of 2% of the project cost as a part of CER activity as per the OM F No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&amp;CC and other instructions issued from time-to-time and this shall be monitored by PCB.</p>
<p><b>Agenda Item: 164.33 &amp; 161.29</b></p>	<p><b>Establishment of Active Pharma Ingredients (Bulk drug and intermediates) manufacturing unit by M/s. Padmavathi Carbons, Plot Nos. 99, 100, 115 &amp; 116, Mega Industrial Park, Kopporthy Village, Chitakommadinne Mandal, Ysr Kadapa District, Andhra Pradesh.</b> SIA/AP/IND2/207080/2021</p>
	<p>Recommendations of the SEAC on 27.07.2021:</p> <p><b>Category : B2-5(f)-API</b></p> <p>The Proposal of <b>M/s. Padmavathi Carbons.</b>, is for Environmental Clearance for production quantities <b>of the bulk drug &amp; Intermediates – 102 TPM</b>. The project proponent and their Consultant M/s Team Labs and Consultants have attended the meeting. MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised, as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes &amp; dye intermediates &amp; bulk drug and intermediates). The Committee noted that this is a bulk drug &amp; intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug &amp; Intermediates manufacturing unit with production capacity: <b>102 TPM</b>. The project proponent has submitted the EMP, PFR, Risk Assessment Reports. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for <b>issue of Environmental Clearance</b> for manufacture of <b>Bulk Drug and Intermediates with production quantity – 102 TPM</b> duly stipulating a condition that the project proponent shall</p>

	<p>submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity and the project proponent shall tie-up with the nearby TSDF for treatment and disposal of hazardous waste.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC and to <b>issue Environmental Clearance with a</b> condition that the project proponent shall (i) tie-up with the nearby TSDF for treatment and disposal of hazardous waste. (ii) allocate funds of 2% of the project cost as a part of CER activity as per the OM F No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&amp;CC and other instructions issued from time-to-time and this shall be monitored by PCB.</p>
<p><b>Agenda Item: 164.34 &amp; 161.30</b></p>	<p><b>Proposed to establish Active Pharma Ingredients (bulk drugs and intermediates) manufacturing facility by M/s. LJS Power LLP (Pharma Division) at Sy. No. 384/2A/2, Garudapuram Village, Kalyanadurg Mandal, Anantapur District, Andhra Pradesh.</b> SIA/AP/IND2/207098/2021</p>
	<p>Recommendations of the SEAC on 27.07.2021:</p> <p><b>Category : B2-5(f)-API</b></p> <p>The Proposal of <b>M/s. LJS Power LLP (Pharma Division),</b> is for Environmental Clearance for production quantities <b>of the bulk drug &amp; Intermediates – 321 TPM.</b> The project proponent and their Consultant, M/s Team Labs and Consultants have attended the meeting. MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes &amp; dye intermediates &amp; bulk drug and intermediates). The Committee noted that this is a bulk drug &amp; intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug &amp; Intermediates manufacturing unit with production capacity: <b>321 TPM.</b> The project proponent has submitted the EMP, PFR, Risk Assessment Reports. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for <b>issue of Environmental Clearance</b> for manufacture of <b>Bulk Drug and Intermediates with production quantity – 321 TPM</b> duly stipulating a condition that the project proponent shall submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity and the project proponent shall tie-up with the nearby TSDF for treatment and disposal of hazardous waste.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC and to <b>issue Environmental Clearance with a</b> condition that the project proponent shall (i) tie-up with the nearby TSDF for treatment and disposal of hazardous waste. (ii) allocate funds of 2% of the project cost as a part of CER activity as per the OM</p>

	F No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&CC and other instructions issued from time-to-time and this shall be monitored by PCB.
<b>Agenda Item: 164.36 &amp; 161.31</b>	<b>Proposed Bulk Drug Intermediates Manufacturing Unit of M/S VAPM Labs Pvt. Limited at Plot No:313/3 Dubacherla Nallagerla(MD) West Godavari District Andhra Pradesh.</b> SIA/AP/IND2/207185/2021
	Recommendations of the SEAC on 27.07.2021: <b>Category : B2-5(f)-API</b> The Proposal of <b>M/S VAPM Labs Pvt. Limited.</b> , is for Environmental Clearance for production quantities <b>of the bulk drug &amp; Intermediates – 200 TPA.</b> The M/s. Hubert Enviro Care have attended the meeting. The proponent has withdrawn the proposal. The committee recommended to with drawl the proposal.  <b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC for with drawl the proposal.
<b>Agenda Item: 164.37 &amp; 161.32</b>	<b>Expansion in the Built Up area from 108325.43 Sq. m to 170922.00 Sq. m at Malkapuram Village, Eluru Mandal, West Godavari, Andhra Pradesh, Eluru, West Godavari, Andhra Pradesh by M/s. Alluri Sitarama Raju Educational Society (ASRAM Hospitals &amp; Medical College).</b> SIA/AP/NCP/54328/2015
	Recommendations of the SEAC on 27.07.2021: <b>Category : B1</b> The proponent and their consultant, M/s SV Enviro labs & consultants have attended the meeting. The committee noted that M/s. Alluri Sitarama Raju Educational Society (ASRAM Hospitals & Medical College) with built-up area 1,08,325.40 Sq. m obtained environmental clearance Dt: 27.11.2015 and Consent for Operation (CFO) Dt: 28.10.2015. Now the project proponent proposes for expansion of the Existing Built up Area from 108325.43 Sq. m to 1,70,922.00 Sq. m. Further the Committee noted that the proposed project falls under Item 8(a) of the schedule of the EIA Notification 2006- Construction projects , as the proposed project site covering built up area is >1,50,000 sq. m. The present proposal comes under category ‘B1’ project. The committee noted that M/s. Alluri Sitarama Raju Educational Society (ASRAM Hospitals & Medical College),has submitted the certified compliance report. The Committee observed that the industry is complying the norms The Committee after examining the project proposals, presentations, MoEF&CC’ Notifications & OMs and detailed deliberations, recommended <b>for issue of Environmental Clearance</b> duly stipulating a condition that the project proponent shall construct the STP for the treatment and disposal of domestic effluents.  <b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC <b>for issue of Environmental Clearance with</b> a condition that the project proponent shall construct the STP for the treatment and disposal of domestic effluents.
<b>Agenda</b>	<b>Proposal for expansion of manufacturing capacity of APIs (Bulk drugs and</b>

<p><b>Item:</b> <b>164.38 &amp;</b> <b>161.33</b></p>	<p><b>Intermediates) in the existing unit located at Sy.No. 57-68, 70-73, 75-77 &amp; 80, Devunipalavalasa Village, Pydibhimavaram Panchayat, Chipurupalli Taluk, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh.by M/s. Dr. Reddy's Laboratories Limited. (API-SEZ) United. SIA/AP/IND2/200679/2021</b></p>
	<p>Recommendations of the SEAC on 27.07.2021: <b>Category : B2-5(f)-API</b></p> <p>The Proposal of <b>M/s. Dr. Reddy's Laboratories Limited.</b>, is for Environmental Clearance for <b>expansion</b> of production quantities <b>of the bulk drug &amp; Intermediates from 1.3 TPD to 7.2 TPD.</b></p> <p>The representative of the project proponent and their Consultant, M/s. TEAM Labs and Consultants., have attended the meeting.</p> <p>MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" Further it is extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021.</p> <p>The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes &amp; dye intermediates &amp; bulk drug and intermediates).</p> <p>The Committee noted that the existing unit is bulk drug &amp; intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug &amp; Intermediates manufacturing unit with expansion of production capacity: from <b>1.3 TPD to 7.2 TPD.</b></p> <p>The project proponent has submitted the EMP, PFR, Risk Assessment Report and certified compliance report of EC order of existing Industry. . <a href="#">The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms.</a></p> <p>The Committee after examining the project proposals, presentations and deliberations recommended for issue of <b>Environmental Clearance</b> for expansion of production of <b>Bulk Drug and intermediates with production quantity from 1.3 TPD to 7.2 TPD</b> duly stipulating a condition that the project proponent shall submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC and to <b>issue Environmental Clearance with a</b> condition that the project proponent shall allocate funds of 2% of the project cost as a part of CER activity as per the OM F</p>

	No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&CC and other instructions issued from time-to-time and this shall be monitored by PCB.
<b>Agenda Item:</b> <b>164.40 &amp; 161.34</b>	<b>Proposed Construction Project : Residential Building project of M/s. SLV Amaravathi Grand II at R.S.Nos: 113/2,113/4. Carmel Nagar, Gunadala, Vijayawada urban, Krishna District, Andhra Pradesh (SIA/AP/MIS/211209/2021)</b>
	This proposal was already appraised in the 159 <sup>th</sup> SEAC meeting held on 26 <sup>th</sup> - 28 <sup>th</sup> May, 2021.  <b>Decision of SEIAA:</b> The proposal was appraised in the 159 <sup>th</sup> SEAC meeting, but the appraisal report yet to be received by SEIAA. The SEAC is requested to expedite.
<b>Agenda Item:</b> <b>164.42 &amp; 161.35</b>	<b>"SLV GREEN MEADOWS (Proposed New Residential Independent Villas), Sy.No's: 15,16,17, Ramavarappadu, Vijayawada Rural, Krishna District, Andhra Pradesh . SIA/AP/MIS/213091/2021</b>
	Recommendations of the SEAC on 27.07.2021: <b>Category : B2</b>  The project proponent and their consultant M/s. Sai Manasa Pvt. Ltd. have attended the meeting.  The Committee noted that the project proponent proposes for construction of <b>Residential Independent Villas</b> project in the site area of <b>92706 sq.m</b> and built up area is <b>93695.14 sq.m</b>  Further the Committee noted that the proposed project falls under Item 8(a) of the schedule of the EIA Notification 2006- Construction projects , as the proposed project site covering an area is < 50 ha and built up area is <1,50,000 sq. m. The present proposal comes under category 'B2' project.  The Committee after examining the project proposals, presentations, MoEF&CC' Notifications & OMs and detailed deliberations, recommended <b>for issue of Environmental Clearance</b> duly stipulating a condition that the project proponent shall construct the STP for the treatment and disposal of domestic effluents.  <b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC <b>for issue of Environmental Clearance with</b> a condition that the project proponent shall construct the STP for the treatment and disposal of domestic effluents.
<b>Agenda Item:</b> <b>164.43 &amp; 161.36</b>	<b>Proposed Active Drug Intermediates Manufacturing Unit by M/s. Sri SPR Biologics Private Limited, Located at Sy.no. 1002, Jangamaheswarapadu Village, Durgi Mandal, Guntur District Andhra Pradesh SIA/AP/IND2/197724/2021</b>
	<b>Category : B2-5(f)-API</b>

	<p>The Proposal of <b>M/s. Sri SPR Biologics Private Limited.</b>, is for Environmental Clearance for production quantities <b>of the bulk drug &amp; Intermediates - 50.04 TPM</b></p> <p>The project proponent and their Consultant M/s. Space Enviro Solutions., have attended the meeting.</p> <p>MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" Further it is extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021.</p> <p>The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes &amp; dye intermediates &amp; bulk drug and intermediates).</p> <p>The Committee noted that this is a bulk drug &amp; intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug &amp; Intermediates manufacturing unit with production capacity: <b>50.04 TPM</b></p> <p>The project proponent has submitted the EMP, PFR, Risk Assessment Report. <a href="#">The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms.</a></p> <p>The nearby Reserve Forest is about 260 meters from the proposed project site. The Committee after examining the project proposals, presentations and deliberations recommended for <b>issue of Environmental Clearance</b> for manufacture of <b>Bulk Drug and Intermediates with production quantity – 50.4 TPM</b> duly stipulating a condition that (i) the project proponent shall submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity. (ii) The project proponent shall obtain the NOC from the Forest Department.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC to <b>issue Environmental Clearance with the</b> condition that the project proponent shall (i) The project proponent shall obtain the NOC from the Forest Department. (ii) allocate funds of 2% of the project cost as a part of CER activity as per the OM F No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&amp;CC and other instructions issued from time-to-time and this shall be monitored by PCB.</p>
<p><b>Agenda Item: 164.44 &amp; 161.37</b></p>	<p><b>Proposed Active Drug Intermediates Manufacturing Unit by M/s. Maithili Pharma Private Limited, Located at Plot No.20, APIIC Industrial Park, Gajulamandyam, Renigunta Mandal, Chittoor District Andhra Pradesh</b></p>



	SIA/AP/IND2/194294/2021
	<p><b>Category : B2-5(f)-API</b></p> <p>The Proposal of <b>M/s. Maithili Pharma Private Limited.</b>, is for Environmental Clearance for production quantities <b>of the bulk drug &amp; Intermediates - 48.45 TPM.</b></p> <p>The project proponent and their Consultant M/s. Pridhvi Envirotech (P) Ltd have attended the meeting.</p> <p>MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021.</p> <p>The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes &amp; dye intermediates &amp; bulk drug and intermediates).</p> <p>The Committee noted that this is a bulk drug &amp; intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug &amp; Intermediates manufacturing unit with production capacity: <b>48.45 TPM.</b> The project proponent has submitted the EMP, PFR, Risk Assessment Reports.</p> <p><a href="#">The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms.</a></p> <p>The Committee after examining the project proposals, presentations and deliberations recommended for <b>issue of Environmental Clearance</b> for manufacture of <b>Bulk Drug and Intermediates with production quantity – 48.45 TPM</b> duly stipulating a condition that the project proponent shall submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity.</p> <p><b>Decision of SEIAA:-</b> Agreed with the recommendation of the SEAC to <b>issue Environmental Clearance with a</b> condition that the project proponent shall allocate funds of 2% of the project cost as a part of CER activity as per the OM F No.22-65/2017-IA.III, dated 01.05.2018 issued by MoEF&amp;CC and other instructions issued from time-to-time and this shall be monitored by PCB.</p>
<b>Agenda No. 166.78 &amp; 161.38</b>	<b>Expansion of Bulk Drugs and Intermediates Manufacturing Unit and Inclusion of Captive power plant of 2 x 2 MW by M/s. SMS Pharmaceuticals Limited, Unit VII at Sy.Nos. 160, 161, 163 to 168 and 170 (Kandivalasa Village), Sy. No. 72 (Kovvada Agraharam Village), Pusapatirega Mandal, Vizianagaram District, Andhra Pradesh.</b>

	(SIA/AP/IND2/151794/2020)
	<p>The issue was earlier examined in the the State Expert Appraisal Committee (SEAC),A.P., in its meeting held on <b>04.03.2021 &amp; 05.03.2021</b> and minutes of the meeting is as follows:</p> <p>The Proposal of M/s. SMS Pharmaceuticals Limited., is for Environmental Clearance for expansion of production quantities of the existing permitted bulk drugs and intermediates 179.05 TPM to 740.76 TPM and Co-generation Power Plant of 2 x 2 MW capacity.</p> <p><b>This proposal was earlier examined in the SEAC meetings held on 8<sup>th</sup> -11<sup>th</sup> December, 2020.</b></p> <p>MoEF&amp;CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&amp;CC Office Memorandum dated 13.04.2020, wherein "<i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" Further it is extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020.</p> <p>The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes &amp; dye intermediates &amp; bulk drug and intermediates).</p> <p>The Committee noted that the PP has proposed expansion of the Bulk Drug &amp; Intermediates manufacturing unit with production capacity from 179.05 TPM to 740.76 TPM. The project proponent has submitted the EMP, PFR, Risk Assessment Reports. The Committee noted that <b>earlier the issue was examined by the SEIAA ,A.P., in its meeting held on 15.12.2020</b> and refer to SEAC to examine the CRZ clearance and recent certified compliance report of the earlier EC and CFO conditions.</p> <p>Now , the representative of the project proponent and their Consultant M/s. Team Labs and Consultants, have attended the meeting.</p> <p>The committee noted that as per EIA Notification,2006 under E(P) Act, 1986, as amended vide S.O.1599 (E) dated 25<sup>th</sup> June, 2014 and MoEF&amp;CC Office Memorandum F.No.22-24/2018-IA.III, dated 23<sup>rd</sup> January, 2019, provides exemption of Environmental Clearance for Thermal Power Plant using Waste Heat Recovery Boilers (WHRB) without any auxiliary fuel.</p> <p>The committee noted that regarding CRZ clearance , the APCZMA vide letter No.178/CRZ/IND/2019-25,dated 21.05.2020., issued No Objection Certificate (NOC) for the proposal for enhancement in the discharge of treated effluent ( from193 KLD to 897 KLD) into sea through existing pipeline at Tammayapalem (H), Pathivada Village, Pusapatirega Mandal, Vizianagaram District, A.P.</p> <p>The committee noted that the project proponent is awaiting certified compliance from the MoEFCC/APPCB since December 2020 (More than 90 days) and in the absence of no report from the RA, the committee considered the self compliance submitted to the SEIAA/APPCB, and made recommendations.</p> <p>The Committee after examining the project proposals, presentations, APCZMA recommendations, MoEF&amp;CC' OMs and detailed deliberations, recommended</p>

<p>for issue of Environmental Clearance for the proposal for Expansion of production of Bulk Drug and intermediates with production quantity from 179.05 TPM to 740.76TPM and Co-generation Power Plant of 2 x 2 MW capacity without any auxiliary fuel, and CRZ Clearance for the proposal for enhancement in the discharge of treated effluent ( from193 KLD to 897 KLD) into sea through existing pipeline</p> <p><b>The issue was placed before the SEIAA in its meeting held on 20.06.2021, 22.06.2021 and 23.06.2021.</b></p> <p><b>Decision of SEIAA:</b> It is observed that the project proposal is appraised with the self compliance report submitted by the proponent. The proposal shall be appraised with certified compliance. It is completed 6 months from the date of submission of requisition for certified compliance. Refer back to SEAC to appraise the proposals with latest certified compliance from MoEF&amp;APPCB and made recommendations.</p> <p>Subsequently, <b>the SEAC, A.P. addressed a letter to M/s. SMS Pharmaceuticals Ltd., on 07.07.2021,</b> requested to submit the latest certified compliance report from MoEF / APPCB to the SEAC, A.P., for further processing.</p> <p>The industry vide letter dated 03.08.2021 addressed the SEIAA,A.P, submitted the certified compliance report of MoEFCC ,RO, Chennai and informing “<i>There are no further expansion/development or activity takes place after issue of certified compliance report dated 20.11.2017.kindly taking into certified compliance report received from regional office of MoEFCC, Chennai process our application for issue of EC.</i>”</p> <p><b>The committee examined the certified EC compliance report of the existing industry. (APPCB report dated 21.08.2021) (Lr.No. PCB/ROVZ/Tech/Z-439/2021, Dated 21.08.2021) and committee noted the industry is complying the norms.</b></p> <p>The Committee after examining the project proposals, presentations, APCZMA recommendations, MoEF&amp;CC’ OMs and detailed deliberations, <b>recommended for issue of Environmental Clearance for the proposal for Expansion</b> of production of Bulk Drug and intermediates with production quantity from 179.05 TPM to 740.76TPM and Co-generation Power Plant of 2 x 2 MW capacity without any auxiliary fuel, and CRZ Clearance for the proposal for enhancement in the discharge of treated effluent ( from193 KLD to 897 KLD) into sea through existing pipeline.</p> <p><b>Decision of the SEIAA:</b> The SEIAA examined the NOC dt 21.05.2020 from APCZMA &amp; the recommendations of SEAC and agreed with the recommendation of the SEAC to issue Environmental Clearance.</p>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Special Secretary To Govt

Dr. P.V.Chalapathi Rao, I.F.S Dr. Thatiparthi Byragi Reddy

Sri P.Venkata Rami  
Reddy, I.A.S,  
(Retired).

Special Secretary to Govt., Professor. Department of  
Environment, Forests, Sciences Environmental Sciences, Andhra  
and Technology Department, University, Visakhapatnam  
Govt. of Andhra Pradesh &  
Member Secretary,  
SEIAA,A.P.

Chairman,  
SEIAA,A.P